Haemophilus influenzae type b vaccine formulation and risk of childhood leukaemia
2002

Vaccine Formulations and Childhood Leukaemia Risk

Sample size: 125129 publication Evidence: moderate

Author Information

Author(s): Groves F, Sinha D, Auvinen A

Primary Institution: Medical University of South Carolina

Hypothesis

Does the formulation of the Haemophilus influenzae type b vaccine affect the risk of childhood leukaemia?

Conclusion

The study found no significant difference in the risk of childhood leukaemia between the two vaccine formulations.

Supporting Evidence

  • 80 cases of childhood leukaemia were diagnosed among subjects born during the trial period.
  • 35 cases were in the PRP-D arm and 45 in the HbOC arm.
  • The relative risk for the HbOC group was 1.14, indicating no significant difference.

Takeaway

This study looked at whether different types of a vaccine could change the chances of kids getting leukaemia, and it found that they didn't.

Methodology

A nation-wide vaccine trial compared two formulations of the Hib vaccine among children born in Finland between 1987 and 1989.

Potential Biases

The design minimized bias and confounding, but individual vaccination verification was not possible.

Limitations

The study could not verify individual vaccination status despite a high participation rate.

Participant Demographics

Children born in Finland between 1987 and 1989.

Statistical Information

Confidence Interval

95% CI 0.63–2.08

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600489

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication